PURPOSE: To investigate metabolic parameters from baseline MATERIALS AND METHODS: From 142 LABC in 137 patients (bilateral-synchronous BC: 5/137), the following parameters from baseline (pre-treatment) RESULTS: 74/142 tumors were "Luminal A/B HER2-", 44/142 "Luminal B HER2+/HER2+", 24/142 TNBC
pCR after NAC occurred in 26/142 tumors (18.3%) and disease recurrence at follow-up (45 ± 18.1 months) in 25/127 assessable patients (19.7%). Significant or suggestive predictors of NAC response, in Luminal A/B HER2-: lower spleen SUVmax and patients' age (OR 0.06
0.93) for pCR
lower TLRmax, TLRmean and BLRmax (OR 1.33
1.22
and 26.42) for residual disease. Significant negative RFS predictors: higher SUVmax, SUVmean, SUVpeak (HR 1.10
1.15
1.11), TLRmax and TLRmean (HR 1.02
1.00), MTV and TLG (HR 1.32
1.26) in Luminal A/B HER2-
higher spleen SUVmax, PET-positive nodes' number and patients' age (HR 6.24
1.20
1.08) in Luminal B HER2+/HER2+. CONCLUSION: Primary tumor and lymphoid organs parameters at baseline